Cell Membrane Blebbing for Rapid, High-Yield Vesicle Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing extracellular vesicles (EVs) face challenges with low yield, inefficiency, and variability, limiting their application in drug delivery, viral gene therapy, and immunotherapy, particularly due to issues with immunogenicity and production scalability.
Innovation Solution
The use of sulfhydryl blocking agents like N-ethylmaleimide (NEM) or photosensitizers such as AlPcS2A, combined with light exposure, induces rapid and efficient production of micro and nanoscale cell vesicles, which can encapsulate AAV and maintain antigenic profiles, enabling controlled size and functionalization for targeted therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional EV production methods are used, then production scalability is limited, but yield and efficiency remain low
Solution Approach 1:
The patent applies parameter changes by modifying chemical parameters (adding sulfhydryl blocking agents like NEM or photosensitizers like AlPcS2A) and physical parameters (light exposure) to induce cell membrane blebbing. This chemical and physical parameter modification transforms the production process, enabling rapid and efficient EV formation with high yield and scalability while maintaining production ease
2Reliability
If viruses are used for gene delivery, then delivery efficacy is improved, but immunogenicity and toxicity increase
Solution Approach 1:
The patent extracts the beneficial delivery function from viral vectors while removing the harmful immunogenic components. By using EVs produced through induced membrane blebbing, the system achieves effective cargo delivery without the immunogenicity and toxicity associated with viral vectors, as EVs are naturally derived and less immunogenic
Solution Approach 2:
The patent creates a non-viral copy of viral delivery functionality. EVs serve as synthetic alternatives that replicate the effective delivery mechanism of viruses without their pathogenic properties, providing a safer platform for gene therapy and drug delivery
3Reliability
If AAV is used for gene therapy, then transduction efficiency is improved, but immune clearance increases
Solution Approach 1:
The patent implements nesting by encapsulating AAV particles within EVs. The EV acts as an outer shell or carrier that protects the nested AAV from immune recognition and clearance. This nested structure allows AAV to maintain its high transduction efficiency while the EV shield prevents immune system detection and neutralization
4Reliability
If whole-cell vaccine formulations are used, then immune activation is improved, but variability increases
Solution Approach 1:
The patent extracts the essential immune-activating components from whole cells and concentrates them into EVs. This extraction process creates a standardized, purified formulation that maintains immune activation capability while eliminating the inherent variability of whole-cell preparations, resulting in more consistent and reproducible vaccine formulations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for high-yield, rapid production of customized ICVs that effectively shield AAV from immune response, maintain maturation characteristics, and enhance therapeutic efficacy, providing a safer and more potent alternative to traditional methods.
Implementation Method 1
The use of sulfhydryl blocking agents like N-ethylmaleimide (NEM) or photosensitizers such as AlPcS2A, combined with light exposure, induces rapid and efficient production of micro and nanoscale cell vesicles
Implementation Method 2
The use of sulfhydryl blocking agents like N-ethylmaleimide (NEM) or photosensitizers such as AlPcS2A, combined with light exposure, induces rapid and efficient production of micro and nanoscale cell vesicles
Data Source
AI summary
The disclosure provides compositions comprising bioorthogonally-conjugated induced cellular vesicles (ICVs) derived from mammalian cells that comprise one or more functional moieties that have been conjugated to the surface of the ICVs by using bioorthogonal chemistry, and applications thereof, including methods of treatment and methods of making the bioorthogonally-conjugated ICVs.